Literature DB >> 16584113

Polymorphism of the fractalkine receptor CX3CR1 and systemic sclerosis-associated pulmonary arterial hypertension.

Bianca Marasini1, Roberta Cossutta, Carlo Selmi, Maria Rosa Pozzi, Marco Gardinali, Marco Massarotti, Maddalena Erario, Lodovica Battaglioli, Maria Luisa Biondi.   

Abstract

Fractalkine (FKN) and its receptor CX3CR1 are critical mediators in the vascular and tissue damage of several chronic diseases, including systemic sclerosis (SSc) and pulmonary arterial hypertension (PAH). Interestingly, the V249I and T280M genetic polymorphisms influence CX3CR1 expression and function. We investigated whether these polymorphisms are associated with PAH secondary to SSc. CX3CR1 genotypes were analyzed by PCR and sequencing in 76 patients with limited SSc and 204 healthy controls. PAH was defined by colorDoppler echocardiography. Homozygosity for 249II as well as the combined presence of 249II and 280MM were significantly more frequent in patients with SSc compared to controls (17 vs 6%, p = 0.0034 and 5 vs 1%, p = 0.0027, respectively). The 249I and 280M alleles were associated with PAH (odd ratio [OR] 2.2, 95% confidence interval [CI] 1.01-4.75, p = 0.028 and OR 7.37, 95%CI: 2.45-24.60, p = 0.0001, respectively). In conclusion, the increased frequencies of 249I and 280M CX3CR1 alleles in a subgroup of patients with SSc-associated PAH suggest a role for the fractalkine system in the pathogenesis of this condition. Further, the 249I allele might be associated with susceptibility to SSc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16584113      PMCID: PMC2270742          DOI: 10.1080/17402520500303297

Source DB:  PubMed          Journal:  Clin Dev Immunol        ISSN: 1740-2522


  10 in total

1.  Role of the CX3CL1-CX3CR1 axis in chronic inflammatory lung diseases.

Authors:  Jianliang Zhang; Jawaharlal M Patel
Journal:  Int J Clin Exp Med       Date:  2010-08-10

2.  Associations of fractalkine receptor (CX3CR1) and CCR5 gene variants with hypertension, diabetes and atherosclerosis in chronic renal failure patients undergoing hemodialysis.

Authors:  Binnur Bagci; Gokhan Bagci; Can Huzmeli; Ilhan Sezgin; Ozturk Ozdemir
Journal:  Int Urol Nephrol       Date:  2016-04-27       Impact factor: 2.370

3.  Increased serum levels of fractalkine and mobilisation of CD34+CD45- endothelial progenitor cells in systemic sclerosis.

Authors:  Audrey Benyamine; Jérémy Magalon; Sylvie Cointe; Romaric Lacroix; Laurent Arnaud; Nathalie Bardin; Pascal Rossi; Yves Francès; Fanny Bernard-Guervilly; Gilles Kaplanski; Jean-Robert Harlé; Pierre-Jean Weiller; Philippe Berbis; David Braunstein; Elisabeth Jouve; Nathalie Lesavre; Françoise Couranjou; Françoise Dignat-George; Florence Sabatier; Pascale Paul; Brigitte Granel
Journal:  Arthritis Res Ther       Date:  2017-03-20       Impact factor: 5.156

4.  Tanreqing Injection Regulates Cell Function of Hypoxia-Induced Human Pulmonary Artery Smooth Muscle Cells (HPASMCs) through TRPC1/CX3CL1 Signaling Pathway.

Authors:  Yonghong Xiang; Fei Zheng; Qinzhe Zhang; RunJuan Zhang; Haiyan Pan; Zongdong Pang; Shimin Dai; Yurong Zhang; Ye Wu; Lunkai Yao; Mengju Su; Luying Lan
Journal:  Oxid Med Cell Longev       Date:  2022-02-11       Impact factor: 6.543

5.  Pathological role of fractalkine/CX3CL1 in rheumatic diseases: a unique chemokine with multiple functions.

Authors:  Brian Jones; Alisa E Koch; Salahuddin Ahmed
Journal:  Front Immunol       Date:  2012-01-02       Impact factor: 7.561

6.  Type I interferon induces CX3CL1 (fractalkine) and CCL5 (RANTES) production in human pulmonary vascular endothelial cells.

Authors:  M Nakano; T Fujii; M Hashimoto; N Yukawa; H Yoshifuji; K Ohmura; A Nakaizumi; T Mimori
Journal:  Clin Exp Immunol       Date:  2012-10       Impact factor: 4.330

7.  Impact of interleukin-6 on hypoxia-induced pulmonary hypertension and lung inflammation in mice.

Authors:  Laurent Savale; Ly Tu; Dominique Rideau; Mohamed Izziki; Bernard Maitre; Serge Adnot; Saadia Eddahibi
Journal:  Respir Res       Date:  2009-01-27

8.  Augmented concentrations of CX3CL1 are associated with interstitial lung disease in systemic sclerosis.

Authors:  Anna-Maria Hoffmann-Vold; Stephen Samuel Weigt; Vyacheslav Palchevskiy; Elizabeth Volkmann; Rajan Saggar; Ning Li; Øyvind Midtvedt; May Brit Lund; Torhild Garen; Michael C Fishbein; Abbas Ardehali; David J Ross; Thor Ueland; Pål Aukrust; Joseph P Lynch; Robert M Elashoff; Øyvind Molberg; John A Belperio
Journal:  PLoS One       Date:  2018-11-20       Impact factor: 3.240

9.  Natural Killer Cells Exhibit a Peculiar Phenotypic Profile in Systemic Sclerosis and Are Potent Inducers of Endothelial Microparticles Release.

Authors:  Audrey Benyamine; Jérémy Magalon; Florence Sabatier; Luc Lyonnet; Stéphane Robert; Chloé Dumoulin; Sophie Morange; Karin Mazodier; Gilles Kaplanski; Martine Reynaud-Gaubert; Pascal Rossi; Françoise Dignat-George; Brigitte Granel; Pascale Paul
Journal:  Front Immunol       Date:  2018-07-18       Impact factor: 7.561

Review 10.  Emerging Role of Fractalkine in the Treatment of Rheumatic Diseases.

Authors:  Yoshiya Tanaka; Kana Hoshino-Negishi; Yoshikazu Kuboi; Fumitoshi Tago; Nobuyuki Yasuda; Toshio Imai
Journal:  Immunotargets Ther       Date:  2020-11-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.